Kailera Therapeutics
Obesity/metabolic small-molecule & peptide GLP-1 portfolio (licensed from Hengrui)
KLRA · Nasdaq · United States
Share price · KLRA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KLRA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 20 Oct 2026+12.8%
Nothing announced by KLRA that day or the session before.
- 9 Oct 2026+16.1%
Nothing announced by KLRA that day or the session before.
- 24 Sep 2026-8.8%
Nothing announced by KLRA that day or the session before.
- 21 Sep 2026-6.5%
Nothing announced by KLRA that day or the session before.
- 9 Sep 2026-9.7%
Nothing announced by KLRA that day or the session before.
- 28 Aug 2026-12.5%
Nothing announced by KLRA that day or the session before.
- 22 Jun 2026+15.0%
Nothing announced by KLRA that day or the session before.
Share of unusual movement by asset
For each asset, the share of KLRA's own-move activity since 20 Apr 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
ribupatideevents and moves
| 2 | shown from 8 days |
Safiglipron (HRS-7535)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 3% |
| Other company news (earnings, financing, releases naming no asset) | — | 8% |
| Sessions with no dated event | — | 90% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1/GIP receptor (dual)Peptide | ObesityType 2 DiabetesHeart FailureAtherosclerotic Cardiovascular Disease | |
| Phase 3 | GLP-1 receptorSmall molecule | ObesityType 2 DiabetesHypertensionHeart FailureChronic Kidney Disease | |
| Phase 2 | GLP-1/GIP/glucagon receptor (triple)Peptide | Obesity |
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (3)
2028 (3)
2031 (1)
May 2031 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $85M | $107M+ $795M short-term inv. | $96M-$134M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $101M | $130M+ $786M short-term inv. | $111M-$78M operating cash flow | report ↗ |
| 2026-Q1 | — | $71M | $112M+ $407M short-term inv. | $79M-$68M operating cash flow | report ↗ |
| 2025-Q3 | — | $27M | $98M | $40M-$30M operating cash flow | report ↗ |
| 2025-Q2 | — | $20M | $101M | $29M-$26M operating cash flow | report ↗ |
| 2025-Q1 | — | $10M | $102M | $18M-$18M operating cash flow | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $160M+ $386M short-term inv. | — | report ↗ |
Kailera Therapeutics reported cash and equivalents of $160.27M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
Insider transactions
Open-market activity, trailing 12 months: 5 purchases ($326.8M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-07 | Nicholson Nur · Chief Technology Officer | Award / grant (derivative) | 220,000 | — | — | Form 4 |
| 2026-07-06 | Tregoning Kathleen · See Remarks | Award / grant (derivative) | 175,000 | — | — | Form 4 |
| 2026-06-09 | Renaud Ronald C JR · director, CEO & President | Option exercise | 38,094 | $5.25 | $200K | Form 4 |
| 2026-06-09 | Renaud Ronald C JR · director, CEO & President | Option exercise (derivative) | 38,094 | — | — | Form 4 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. · 10% owner | Conversion | 9,477,719 | — | — | Form 4 |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK · 10% owner; 10% owner | Conversion | 10,276,820 | — | — | Form 4 |
| 2026-04-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. · 10% owner | Conversion | 2,034,133 | — | — | Form 4 |
| 2026-04-20 | RTW INVESTMENTS, LP; WONG RODERICK · 10% owner; 10% owner | Open-market purchase | 500,000 | $16.00 | $8.0M | Form 4 |